BMY - Bristol-Myers Squibb Company

Market Overview

Price: $59.39 (as of April 21, 2026)
Market Cap: $121.3B
Sector: Pharmaceuticals
Exchange: NYSE

Recent Performance

1-day change: +0.44%
1-week change: +2.26%
1-month change: +3.32%
YTD: +10.1%

Short Interest Analysis

Current Short Interest (April 21, 2026):

Short Interest % of Free Float: 1.35%
Shares Short: 27.43M
Short Interest Value: $1.63B
Days to Cover (DTC): 0.71 days
Change (1 week): -5.74%
Change (1 month): +5.37%

Bristol-Myers Squibb shows low short interest at just 1.35% of free float. This is a very modest level of short activity for a large-cap pharmaceutical stock. Short interest declined by 5.74% over the past week, indicating some short covering. However, it's up 5.37% over the past month.

The days to cover metric of 0.71 is extremely low, meaning shorts could theoretically cover their entire positions in less than one trading day based on average volume. This suggests minimal short-term squeeze potential.

Historical Trend: Short interest peaked at 1.74% on March 23 and has since declined to the current 1.35% level, a drop of about 22% from the peak.

Cost to Borrow & Utilization

Cost to Borrow:

Current CTB: 0.38% (April 21)
1-week change: -34.0%
1-month change: -50.3%

The cost to borrow has dropped significantly, now at just 0.38% APR. This is extremely low and indicates ample supply of shares available for shorting. The sharp decline suggests borrowing demand has eased considerably.

Utilization:

Current: 0.28%
52-week high: 3.56%

Utilization is extremely low at 0.28%, meaning only a tiny fraction of available shares have been lent out. This reinforces that there's very little shorting pressure on BMY.

Availability: 9,999% of short interest (essentially unlimited shares available to borrow)

Options Activity

Put/Call Ratio (PCR):

Current PCR: 0.91 (April 21)
20-day mean: 0.93
Z-score: -0.77 (below average)
52-week range: 0.68 - 1.12

The put/call ratio of 0.91 is slightly below the 20-day average, suggesting a mild tilt toward bullish sentiment in the options market. The negative Z-score indicates more call buying relative to recent norms, though the signal is moderate.

Valuation & Fundamentals

ORTEX Stock Score: 74.65 (out of 100)

This is a strong composite score indicating BMY ranks well across multiple fundamental and technical factors.

Key Metrics:

Forward Dividend Yield: 4.31%
Analyst Return Potential: +6.15% (upside to average target price)
RSI (14-day): 51.37 (neutral territory)

The 4.31% dividend yield is attractive for income investors and is well above the market average. Analyst consensus suggests modest upside of about 6% from current levels.

Upcoming Events

Next Earnings: Q1 2026 Earnings Call on April 24, 2026 at 4:30 PM ET

BMY reports earnings in just 2 days. Investors will be watching for:

Pipeline updates (drug development progress)
Revenue guidance amid patent cliff concerns
Performance of key drugs like Opdivo, Eliquis, and Revlimid

Summary

BMY shows minimal short interest and extremely low borrowing costs, suggesting very little bearish pressure. The stock has posted solid gains over the past month (+3.3%) and YTD (+10.1%). With earnings due April 24, options activity is showing a slight bullish tilt.

The 4.31% dividend yield and strong ORTEX Stock Score of 74.65 make BMY appealing for quality-focused investors. Short interest metrics offer no squeeze catalyst, but the low cost to borrow and utilization indicate a stable borrowing environment.

This is not financial advice. Data sourced from ORTEX as of April 22, 2026.

BMY - Bristol-Myers Squibb Company